Clariane SEFRA:KO2 +1.50%60 ROE % is 3.34% as of Dec. 2025, which is 62% above its 10-year median of 2.06. GuruFocus rates FRA:KO2 with a GF Score™ of 60/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Clariane SE ranks worse than 68.79% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Clariane SE's annualized net income for the quarter that ended in Dec. 2025 was €120 Mil. Clariane SE's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €3,600 Mil. Therefore, Clariane SE's annualized ROE % for the quarter that ended in Dec. 2025 was 3.34%.
The historical rank and industry rank for Clariane SE's ROE % or its related term are showing as below:
FRA:KO2'
s ROE % Range Over the Past 10 Years
Min: -2.96 Med: 2.06 Max: 7.28
Current: 0.04
During the past 13 years, Clariane SE's highest ROE % was 7.28%. The lowest was -2.96%. And the median was 2.06%.
FRA:KO2's ROE % is ranked worse than 68.79% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs FRA:KO2: 0.04
Clariane SE (FRA:KO2) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Clariane SE ROE % Related Terms
Clariane SE ROE % Historical Data
* Premium members only.
The historical data trend for Clariane SE's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Clariane SE's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's ROE % distribution charts can be found below:
* The bar in red indicates where Clariane SE's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Clariane SE (FRA:KO2) has a ROE % of 3.34% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Clariane SE and its competitors. This is 62% above median its historical median of 2.06. According to the industry distribution chart, Clariane SE ranks #432 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 68.8%.
Is Clariane SE's ROE % too high?
Clariane SE's current ROE % of 3.34% is 62% above median its 10-year median of 2.06. The Healthcare Providers & Services industry median ROE % is 5.72. Clariane SE's value of 3.34% is 41.6% below this industry median. Based on the distribution chart, Clariane SE ranks #432 out of 628 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Clariane SE has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #432 out of 628 companies for ROE %. This places Clariane SE in the lower half of its industry. The industry median ROE % is 5.72. Clariane SE's value of 3.34% is 41.6% below this benchmark. While the company's 10-year median is 2.06 vs. the industry median of 5.72, Clariane SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current ROE % of 3.34% is 41.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current ROE % is 3.34%, which is 62% above median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.20 — trading 70.1% above its estimated fair value. The current ROE % is 3.34%, which is 62% above median its 10-year median of 2.06 and 41.6% below the Healthcare Providers & Services industry median of 5.72. Clariane SE's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current ROE % is 3.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (FRA:KO2) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.20 is trading 70.1% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for FRA:KO2:
ROE %: 3.34% (62% above median its 10-year median of 2.06)
GF Value™: €2.47 vs. price of €4.20 (70.1% above fair value)
Industry Position: 41.6% below the Healthcare Providers & Services median (#432 of 628)
No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
60GF Score
Get the complete analysis for FRA:KO2
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KO2 has been successfully added to your 
